BeyondSpring Inc.
BYSIHealthcare|Biotechnology|US
$0.63
-0.01 (-1.01%)
DCF Value
$0.18
Cash / Share
$0.16
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05130827 Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | Multiple Myeloma | P2 | Active | 17 | Open-label | Plinabulin |
| NCT05599789 Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | Non Small Cell Lung Cancer Metastatic | P2 | Active | 47 | Open-label | Pembrolizumab in Combination with Plinabulin and Docetaxel |
| NCT02504489 Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC | Non-Small Cell Lung Cancer | P3 | Completed | 559 | RCT, Single-blind | Docetaxel + Plinabulin (DP), Docetaxel (D) |
| NCT03294577 Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia | Chemotherapy-induced Neutropenia | P3 | Unknown | 221 | RCT, Double-blind | Pegfilgrastim, Plinabulin, Docetaxel, doxorubicin, and cyclophosphamide (TAC) |
| NCT07361484 Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) | Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance | P3 | Not Yet Recruiting | 442 | RCT, Double-blind | Plinabulin, Docetaxel, Placebo (matching plinabulin placebo) |
| NCT03102606 Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 | Chemotherapy-induced Neutropenia | P3 | Completed | 105 | RCT, Double-blind | Plinabulin, Pegfilgrastim |
| NCT04345900 Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 | Chemotherapy-induced Neutropenia | P2 | Completed | 55 | RCT, Open-label | Plinabulin, Pegfilgrastim |
| NCT04227990 Plinabulin iv Solution in Prevention of TAC Induced Neutropenia | Chemotherapy-induced Neutropenia | P2 | Completed | 115 | RCT, Open-label | Plinabulin, Pegfilgrastim, Docetaxel, doxorubicin, and cyclophosphamide (TAC) |
| NCT03575793 A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | Lung Cancer, SCLC | P1P2 | Completed | 39 | Open-label | Nivolumab, Plinabulin, Ipilimumab |
| NCT02812667 Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer Metastatic | P1 | Completed | 18 | Open-label | Nivolumab + Plinabulin |